DSM-Firmenich stock downgraded by Deutsche Bank as target rises
Published on 11/17/2026 at 10:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst View Turns More Cautious
- Deutsche Bank now sees a more balanced risk-reward profile after the stock's re-rating.
- The broker still expects operating growth and margin expansion in 2027.
Deutsche Bank downgraded DSM-Firmenich from Buy to Hold on Monday, November 16, while raising its price target to 112 euros from 110 euros, according to Yahoo Finance. The bank said the shares' re-rating has reduced the margin for further gains and placed greater emphasis on delivery against the group's 2028 targets.
Execution Becomes The Main Test
Analyst Virginie Boucher-Ferte said further upside would require organic sales growth of 5-7% and an EBITDA margin of 22-23% in 2028. Deutsche Bank sees risks to both objectives, making operational delivery more important for the valuation case.
The broker nevertheless expects another year of solid organic growth and margin expansion in 2027. Its forecasts are 3% above consensus, while its earnings-per-share estimates are about 1% higher after modest upgrades. Deutsche Bank's revised stance therefore reflects valuation and execution risk rather than a rejection of the company's growth prospects.
DSM-Firmenich stock traded at 104.60 euros on Lang & Schwarz at 10:05 CET on Tuesday, November 17, 2026.
DSM-Firmenich stock at a glance
- Company: DSM-Firmenich AG
- ISIN: CH1216478797
- Ticker: DSFIR.AS
- Lang & Schwarz quote: 104.60 euros on November 17, 2026 at 10:05 CET
The latest view follows Jefferies' downgrade to Hold from Buy on November 11. That earlier call also cited limited room for further valuation expansion after a strong share-price run, while retaining a constructive assessment of parts of the fragrance and nutrition portfolio.
Investors will focus next on whether DSM-Firmenich can convert its volume-led growth and margin improvement into the medium-term targets highlighted by Deutsche Bank. The company's third-quarter update on November 4 raised its 2026 like-for-like sales-growth outlook to around 5% from 2-4% and kept the adjusted EBITDA margin outlook at around 20%.
For broader market context, see Current market reports for the AEX.
